• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IFN gamma protein

Activity

0.02-0.14 ng/mL

Specific Activity

minimally 1.00 x 107 IU/mg

Species Reactivity

human,mouse,pig,rat

Purity

>95%

Cat No : HZ-1301

Print datasheet

Synonyms

IFG, IFI, IFN gamma, IFNG, Immune interferon, Interferon gamma, interferon, gamma

Validation Data Gallery

  • Purity of recombinant human IFN gamma was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

    Purity of recombinant human IFN gamma was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue

  • Recombinant human IFN gamma (HZ-1301) dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

    Recombinant human IFN gamma (HZ-1301) dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

  • Proteintech IFN gamma (HZ-1301) demonstrates a 3-fold lower EC50 and equivalent dose-dependent inhibition of proliferation to a leading competitor. Recombinant human IFN gamma dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

    Proteintech IFN gamma (HZ-1301) demonstrates a 3-fold lower EC50 and equivalent dose-dependent inhibition of proliferation to a leading competitor. Recombinant human IFN gamma dose-dependently inhibits proliferation of the HT-29 human colorectal adenocarcinoma cell line. Cell number was quantitatively assessed by PrestoBlue® cell viability reagent. HT-29 cells were treated with increasing concentrations of recombinant IFN gamma for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model.The EC50 range is 0.02-0.14 ng/mL.

Technical Specifications

GeneID 3458
Species Human
Expression HEK293
Activity 0.02-0.14 ng/mL
Specific Activityminimally 1.00 x 107 IU/mg
Purity >95%
Endotoxin<1 EU/μg
Accession NumberP01579
Molecular Mass 17 and 21 to 32 kDa reduced and non-reduced, homodimer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human,mouse,pig,rat

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human albumin (HSA). Gently swirl or tap vial to mix.

Background

Interferon gamma (IFN γ), is a type II interferon that provides immunity against bacterial, viral and protozoan infections. In its active form, IFN γ is a glycosylated, non-covalently linked homodimer of 17, 21-32 kDa subunits. It is produced by a number of immune cell types including natural killer cells, natural killer T cells, and effector lymphocyte T cells following antigenic and inflammatory triggers. The IFN γ dimer binds to its cognate receptor which has two subunits: IFN-γR1 which is the ligand-binding chain (α chain) and IFN-γR2, the signal-transducing chain (β chain). Binding to the receptor activates the JAK/STAT pathway which in turn activates IFN γ responsive genes. While IFN γ can inhibit viral replication, it also works as an immune-modulator and immune-stimulator by increasing surface expression of class I MHC proteins (PMID: 19268625; 10688427)

Synonyms

IFG, IFI, IFN gamma, IFNG, Immune interferon, Interferon gamma, interferon, gamma

Publications

SpeciesTitle
mouse

Mol Cell

Serine synthesis sustains macrophage IL-1β production via NAD+-dependent protein acetylation

Authors - Chuanlong Wang
View Article
mouse

EMBO Mol Med

Glutathione peroxidase 8 negatively regulates caspase-4/11 to protect against colitis.

Authors - Jye-Lin Hsu
View Article
human

Virulence

The lipoprotein NlpD in Cronobacter sakazakii responds to acid stress and regulates macrophage resistance and virulence by maintaining membrane integrity.

Authors - Xuemeng Ji
View Article
human

Mol Neurobiol

Teriflunomide Promotes Blood-Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis

Authors - Yipeng Zhao
View Article
human

Eur J Pharmacol

Sappanone A ameliorated imiquimod-induced psoriasis-like dermatitis in BALB/c mice via suppressing Mmp8 expression and IL-17 signaling pathway

Authors - Hongyang Li
View Article
human

Cancer Sci

CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.

Authors - Xiaoge Niu
View Article